# Danggui Shaoyao San ameliorates neuroinflammation in a D-galactose-induced Alzheimer’s disease rat model by suppressing the JAK2/STAT3 pathway and modulating Th17/Treg -related immune dysregulation

**Authors:** Gangying Fu, Shuyao Tang, Xin Sun, Jiajun Tong, Mengfen Zhou, Ping Li, Pan Meng, Shaowu Cheng, Zhenyan Song

PMC · DOI: 10.3389/fcell.2026.1763180 · 2026-02-25

## TL;DR

This study shows that Danggui Shaoyao San, a traditional Chinese herbal formula, can reduce brain inflammation and improve memory in a rat model of Alzheimer's disease.

## Contribution

The study reveals a new mechanism by which Danggui Shaoyao San ameliorates Alzheimer's disease through immunomodulation and JAK2/STAT3 pathway inhibition.

## Key findings

- DSS treatment reduced neuronal damage and neuroinflammation in AD rats.
- DSS modulated Th17/Treg-related immune dysregulation in the brain and periphery.
- DSS inhibited JAK2/STAT3 phosphorylation and suppressed pro-inflammatory cytokine production.

## Abstract

This study investigates the therapeutic potential of Danggui Shaoyao San (DSS), a traditional Chinese herbal formula, focusing on its effects on Th17/Treg -associated immune regulation and the JAK2/STAT3 signaling pathway.

Forty male Sprague-Dawley rats were randomly divided into five groups: control, AD model, low-dose DSS (12 g/kg/day, raw herbal materials), high-dose DSS (24 g/kg/day, raw herbal materials), and donepezil (0.5 mg/kg/day). AD models were established by intraperitoneal injection of D-galactose (100 mg/kg/day) for 8 consecutive weeks. Behavioral tests, flow cytometry, biochemical assays, histological analyses, qPCR, and Western blotting were used to evaluate DSS’s effects. Untargeted metabolomics profiled metabolic alterations, while network pharmacology and molecular docking were integrated to predict key targets and pathways.

DSS treatment significantly alleviated neuronal damage, suppressed neuroinflammation, and improved learning and memory deficits in AD rats. Moreover, DSS was associated with alterations in Th17- and Treg-related immune dysregulation both in the brain and periphery. Serum metabolomic identified disruptions lipid metabolism and amino acid metabolism pathways. Network pharmacology and experimental validation indicated that DSS exerts its anti-neuroinflammatory effects by inhibiting JAK2 and STAT3 phosphorylation, reducing their nuclear translocation, and consequently suppressing Th17 differentiation and pro-inflammatory cytokine production.

DSS is a promising candidate for AD treatment, with neuroprotective and cognitive-enhancing properties mediated through immunomodulation and JAK2/STAT3 pathway inhibition.

## Linked entities

- **Proteins:** JAK2 (Janus kinase 2), STAT3 (signal transducer and activator of transcription 3)
- **Chemicals:** D-galactose (PubChem CID 206), doxepin (PubChem CID 3158)
- **Diseases:** Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 25125], Jak2 (Janus kinase 2) [NCBI Gene 24514]
- **Diseases:** neuroinflammation (MESH:D000090862), AD (MESH:D000544), inflammatory (MESH:D007249), learning and memory deficits (MESH:D007859), neuronal damage (MESH:D009410)
- **Chemicals:** D-galactose (MESH:D005690), amino acid (MESH:D000596), donepezil (MESH:D000077265), lipid (MESH:D008055)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12975871/full.md

---
Source: https://tomesphere.com/paper/PMC12975871